附件: RENTW :42 . 用文报 n a man (B 具新技术企业 8 发表网 204 注：从左起瑞银证券有限责任公司执行董事季序我、公司董事会秘书张斌、公司证券事务代 表曾宇婷合影留念。 ...

Group 1: Company Representation - The company board secretary, Zhang Bin, is present in the front row [2] - The company securities representative, Zeng Yuting, is also present in the back row [4] - Various institutional researchers from firms such as Guotai Junan, Chuang Hai Fu Xin, and others are photographed together [5] Group 2: Institutional Collaboration - The collaboration includes institutions like Dongguan Securities, Nuoan Fund, and CITIC Securities [5] - Other participating institutions are Zhongshan Securities, Congrong Investment, Guangdong Yinshi Investment, and Guangdong Huizheng Investment [5] - The presence of Lianxun Securities among the institutional researchers indicates a broad engagement [5]

Group 1: Company Representatives - The company’s securities affairs representative, Zeng Yuting, and board secretary, Zhang Bin, were present with researchers from various investment firms [2][3] Group 2: Institutional Collaborations - Collaborating institutions include Franklin Templeton Securities Investment Trust Co., Ltd., Guosen Securities Co., Ltd., Hanlun Investment Consulting (Shanghai) Co., Ltd., and Future Asset Yicai Investment Consulting (Shanghai) Co., Ltd. [2][3]

Group 1: Interaction Highlights - The chairman of Da An Gene, He Yunshao, and the board secretary, Zhang Bin, engaged with investors during the event [1] Group 2: Visual Documentation - Photos capturing the interaction between the chairman and investors were included in the report [1]

证券代码：002030 证券简称：达安基因 编号：2015004 中山大学达安基因股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------|----------------------------------|------------------------------------------------------| | | √ 特定对象调研 | □ 分析师会议 | | 投资者关系活动 | □ 媒体采访 | □ 业绩说明会 | | 类别 | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 （ ） | | | 参与单位名称及 | 新思路投资副总裁冯昕 | | | 人员姓名 | | | | 时间 | 2015-05-14 （下午 | 14:00- 下午 15：00 ） | | 地点 | 广州市高新技术开发区科学城香山路 | 19 号（公司总部） | | 上市公司接待人 员姓名 | | 董秘张斌、证券事务代表曾宇婷、证券事务专员冯海英 | | 投资者关系活动 | | 调研公司经营和产品的情况（以调研机构提问，公 ...

Group 1: Company Representatives - Company securities representative Zeng Yuting, researcher from Dacheng Fund Management Co., Ltd. Hao Lei, company board secretary Zhang Bin, and researcher from Guotai Junan Securities Yu Suoyang took a group photo [2]

附件： 注：从左起公司董事会秘书张斌、新思路投资副总裁冯昕合影留念。 注：从左起公司董事会秘书张斌、新思路投资副总裁冯昕合影留念。 ...

证券代码：002030 证券简称：达安基因 编号：2015005 中山大学达安基因股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------------|----------------------------------|------------------------------------------------------| | | √ 特定对象调研 | □ 分析师会议 | | 投资者关系活动 | □ 媒体采访 | □ 业绩说明会 | | 类别 | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 （ ） | | | | | 永丰证券投资信托股份有限公司海外投资部基金经理人张乔 | | | | 詠、台新证券投资信托股份有限公司大中华股票投资部资深 | | 参与单位名称及 | | 研究员陈美君、统一证券投资信托股份有限公司投资研究部 | | 人员姓名 | | 研究员林玉珠、上海与贡投资管理中心（有限合伙）投资总 | | | | 监任劲、西藏合众易晟投资管理有限责任公司研究部经理邓 | | | 睿 | | ...

Group 1: Company Overview - The company is called Da An Gene Co., Ltd., with the stock code 002030 [1] - The investor relations activity took place on April 30, 2015, at the company's headquarters in Guangzhou [2] Group 2: Business Focus and Strategy - The current focus of the company is on industrial layout rather than the development of individual segments [2][3] - Each segment of the company's industrial chain is managed by specialized companies to ensure balanced progress [3] Group 3: Market Insights - The market share of the company's second-generation gene sequencing products is currently not available, with data expected by the end of the year [3] - The application of second-generation gene sequencing technology in oncology is still immature, making it difficult to assess its market size [3] Group 4: Future Developments - Da An Gene is closely monitoring advancements in second-generation gene sequencing technology, particularly in oncology, as it is one of the potential application areas [3] - The company is not currently involved in the pharmaceutical sector, focusing primarily on diagnostics [4] Group 5: Corporate Actions - There are no current plans for additional share issuance [4]